Introduction
============

The incidence and mortality rate of esophageal cancer (EC) are ranked as the eighth and sixth highest among all cancers worldwide ([@b1-or-39-05-2136]). China is one of the countries with the highest incidence and mortality of EC in the world. Newly diagnosed EC cases are estimated at 4,292,000 annually, ranking as the third among all cancer cases, and accounting for 2,814,000 cancer-related deaths, which ranks fourth among all cancer cases ([@b2-or-39-05-2136]). It is widely known that the Taihang Mountain region is an area with a high incidence of EC cases located in the junction of Shanxi, Hebei and Henan Province ([@b3-or-39-05-2136]). Esophageal squamous cell carcinoma (ESCC) is the main type of EC and \~70% of worldwide ESCC cases occur in China. The 5-year survival rate of ESCC remains between 10 and 25% due to the absence of clinical approaches for early diagnosis and treatment ([@b4-or-39-05-2136],[@b5-or-39-05-2136]). Therefore, identification of the critical driving genes of ESCC is urgent in order to improve the management of ESCC patients.

In our preliminary experiment, we performed whole-genome sequencing (WGS) of 14 and whole-exome sequencing (WES) of 90 ESCC tumor and adjacent normal tissues from patients recruited from the Taihang Mountain region in China. We identified eight significantly mutated genes (SMGs) including FAT atypical cadherin 1 (FAT1). Among these SMGs, FAT1 was mutated in 15% of ESCC tumors ([@b6-or-39-05-2136],[@b7-or-39-05-2136]). Furthermore, our studies identified a novel role for FAT1 in inhibiting tumor growth and epithelial-mesenchymal transition (EMT) in ESCC by disrupting the MAPK/ERK pathway ([@b8-or-39-05-2136]).

Fat cadherins are extremely large cell adhesion molecules, with \>30 cadherin repeats, including FAT1, FAT2, FAT3, FAT4. FAT1 is an important *trans*-membrane protein involved in the regulation of cell adhesion and growth, migration, actin dynamics and orientation, playing critical roles in tumor development. It is often regarded as a tumor-suppressor gene or oncogene in different types of human cancer ([@b9-or-39-05-2136]--[@b11-or-39-05-2136]). Morris *et al* reported that recurrent somatic mutation of FAT1 was found to lead to aberrant activation of the Wnt/β-catenin signaling pathway in human glioblastoma multiforme ([@b12-or-39-05-2136]). Moreover, depression of FAT1 was found to accelerate cell migration in cholangiocarcinoma and breast cancer ([@b13-or-39-05-2136]). However, it was reported that FAT1 acts as an oncogene in hepatic cancer ([@b11-or-39-05-2136]). Noteworthy, our previous study showed that FAT1 acts as a tumor-suppressor gene in ESCC ([@b8-or-39-05-2136]).

Atomic force microscopy (AFM) has provided a new screening test to observe the morphological and mechanical properties of a single cell ([@b14-or-39-05-2136]). AFM is a type of scanning probe microscopy with high resolution, that can be used to detect changes in cellular biophysical properties, such as roughness, adhesion and elasticity ([@b15-or-39-05-2136],[@b16-or-39-05-2136]). With the development of AFM technology, AFM is used more and more extensively in the tumor field. Kaul-Ghanekar *et al* observed and analyzed breast cancer cell lines by AFM and found that SMAR1 acts as tumor suppressor by regulating expression of cell surface proteins ([@b17-or-39-05-2136]). Cross *et al* reported the stiffness of live metastatic cancer cells taken from the pleural fluids of patients with suspected lung, breast and pancreas cancer. The results showed that mechanical analysis can distinguish cancer cells from normal cells using AFM ([@b18-or-39-05-2136]).

The aim of our present study was to confirm the effect of FAT1 on the migration and invasion of ESCC cell lines YSE2 and Colo680N. Moreover, the cell adhesive force and cell elasticity force after FAT1 knockdown were detected by AFM. The present study will contribute to the understanding of the mechanisms that drive the development and progression of ESCC and may provide a new therapeutic target for ESCC treatment.

Materials and methods
=====================

### Cell culture

All ESCC cell lines used in the study were obtained from the Translational Medicine Research Center, Shanxi Medical University (Taiyuan, China) and cultured in HyClone™ RPMI-1640 medium (GE Healthcare Life Sciences, HyClone Laboratories, Logan, UT, USA) with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a 5% CO~2~ incubator. Culture medium was replaced every two to three days. Subculture was carried out when the cells were fused to 80--90% confluency and logarithmic phase cells were used in the following experiments.

### Ethics statement

All experimental protocols were approved by the Ethics Committee of Shanxi Medical University. All samples were obtained before treatment according to the guidelines of the local ethics committees and written informed consent was received from all participants.

### TMAs and immunohistochemistry (IHC)

Tissue microarrays (TMAs) consisting of 125 primary ESCC tumor tissues and 125 matched non-tumor tissues were obtained from Shanxi Cancer Hospital from 2011 to 2014. IHC was performed to detect the protein expression of the corresponding genes. Briefly, the TMA sections (4 µm) were deparaffinized and rehydrated with xylene and a series of grades of alcohol and then soaked in 3% H~2~O~2~ for 15 min. Antigen retrieval was implemented in sodium citrate buffer (pH 6.0) for 2 min in a pressure cooker, followed by incubation with the anti-FAT1 antibody (1:300 dilution; rabbit polyclonal antibody; cat. no. HPA023882; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 4°C overnight. After washing with PBS, the TMA sections were incubated with the secondary antibody (HRP-polymer anti-mouse/rabbit IHC kit, goat; cat. no. KIT-5920; Maixin Biotechnology, Co., Ltd., Fuzhou, China) at 37°C for 20 min. Slides were stained with DAB and counterstained with hematoxylin. The levels and location of FAT1 were assessed using IHC and analyzed with Aperio Cytoplasma 2.0 software (Leica Microsystems GmbH, Wetzlar, Germany). The protein expression of FAT1 was calculated by a semi-quantitative assessment of both the staining intensity and the percentage of positive cells.

### RNA extraction and reverse transcription PCR (RT-PCR) and quantitative real-time PCR (qPCR)

Total RNA was isolated from cells by TRIzol reagent (Takara Biotechnology Co., Ltd., Dalian, China). RNA (2 µg) was reverse-transcribed in 20 µl using the PrimeScript^®^ RT Master Mix (Perfect Real-Time) for RT-PCR (Takara Biotechnology). The reaction conditions of reverse-transcription PCR were set as follows: 94°C for 5 min, 30 cycles at 94°C for 50 sec, 55°C for 30 sec, and 72°C for 50 sec; followed by extension at 72°C for 10 min. Quantitative real-time PCR (qPCR) experiment was implemented with SYBR^®^ Premix Ex Taq^™^ (Takara Biotechnology). The detailed protocol was as follows: 95°C for 10 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min. The relative expression of target genes was determined by normalization to GAPDH expression and was determined as ΔΔCt. The primers used to measure the expression level of FAT1 were: 5′-TGCTGGAGGAAAAGTTGCTT-3′ (sense), and 5′-GATTACGCCGGACAGTTTGT-3′ (antisense). The primers of GAPDH were: 5′-AGTCAACGGATTTGGTCGTA-3′ (sense), and 5′-AGTCAACGGATTTGGTCGTA-3′ (antisense). The experiment was completed in triplicate independently.

### In-cell western assay

The FAT1 protein in the ESCC cell lines was determined using in-cell western assay. Briefly, 4×10^4^ cells were seeded in 96-well plates and incubated under normal conditions to culture to a final volume of 200 µl/well overnight. The cells were fixed with 4% formaldehyde and permeabilized using 0.2% Triton X-100. LI-COR Odyssey Blocking Buffer (150 µl) (LI-COR Biosciences, Lincoln, NE, USA) was added to each well. The cells were then incubated with the FAT1 primary antibody (1:1,000; rabbit polyclonal antibody; cat. no. ab190242; Abcam, Cambridge, UK). Then, the wells were incubated with corresponding fluorescence stain CellTag^™^ 700 Stain (red fluorescence; LI-COR Biosciences, Lincoln, NE, USA) or fluorescence antibody IRDye^™^ 800CW (green fluorescence; LI-COR Biosciences). Images of FAT1 were obtained using the Odyssey Infrared Imaging System (LI-COR Biosciences GmbH, Bad Homburg, Germany). The protein level of FAT1 was calculated as the ratio of the intensity of FAT1 to that of the cell number. At least three independent experiments were carried out; for each independent experiment, three duplicates were performed for each group.

### Plasmid constructs and transfection

For knockdown of endogenous FAT1, we used vectors containing the sequence: 5′-GCCTGTGGGTTCCAGTGTAAT-3′ (FAT1shRNA1) and 5′-GCTGGAAATGAACTGGATTTC-3′ (FAT1shRNA1) and scramble control sequence: 5′-TTCTCCGAACGTGTCACGTTTC-3′ (NC). These shRNAs were cloned into the vector pGLV-H1-GFP+Puro and co-transfected into 293T cells with packaging plasmids (Shanghai GenePharma Co., Ltd., Shanghai, China). The lentivirus supernatant was used to infect the YSE2 and Colo680N cell lines. The corresponding empty vectors were used as the negative control. Stable cell lines were screened out for 2 weeks with 2 µg/ml puromycin (Invitrogen; Thermo Fisher Scientific, Inc.). The efficiency of silence was determined by means of RT-PCR, qPCR and in-cell western assay.

### Transwell migration and invasion assays

Migration and invasion assays were performed using Transwell plates (pore size is 8-µm; Corning, Inc., Corning, NY, USA). In brief, 50,000 cells were seeded into each well with serum-free medium in the upper compartment of the Transwell plates coated with or without BD Matrigel Basement Membrane Matrix (BD Biosciences, Franklin Lakes, NJ, USA), and the ratio of the Matrigel Basement Membrane Matrix and serum-free medium was 1:6. The lower compartment of the chamber was filled with medium with 10% FBS. Following a 24-h culture, the cell numbers that passed through the membrane were fixed with 4% formaldehyde and stained using 0.1% crystal violet and counted under a microscope (IX71-A12FL/PH; Olympus Corp., Tokyo, Japan).

### Wound healing assay

The stably transfected YSE2 and Colo680N cells were seeded in 6-well plates. When cells grew to 95--100% density, the cell monolayer was scratched using a pipette tip, followed by being washed with culture medium to remove any loosely held cells. The wound closure was monitored at 0 and 24 h after scratching, and the wound area was calculated using ImageJ software (National Institutes of Health, Bethesda, MD, USA). At least three independent experiments were carried out; for each independent experiment, three duplicates were performed for each group.

### Atomic force microscopy (AFM) analysis

The morphology and biomechanical properties of the YSE2-FAT1shRNA and Colo680N-FAT1shRNA cells and the corresponding controls were detected by AFM, as previously described ([@b19-or-39-05-2136]). Briefly, AFM images were acquired in the tapping mode and in contact mode using Si3N4 tips (NSC19, 0.68 N/m normal spring constant; Schaefer Technologie GmbH, Langen, Germany) and gold-coated tips (CSC 38; Schaefer Technologie GmbH), respectively. AFM measurements were performed in aqueous solution at room temperature, using a 5500 atomic force microscope (Agilent Technologies, Inc., Santa Clara, CA, USA). The spring constants of the cantilevers used for AFM force spectroscopy were \~0.1 N/m. Adhesion and elasticity maps were obtained by recording 16×16 force-distance curves on areas of a given size (2×2 µm), calculating the adhesion force and elasticity modulus for each force curve and displaying these values as gray and colorized scale pixels, respectively. These maps qualitatively and quantitatively demonstrated the viscoelasticity of individual cells at the nanoscale level.

### Statistical analyses

Statistical analyses were performed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Experiments were performed in triplicate, and data are presented as the mean ± SEM. Data from two groups were analyzed by unpaired t-test and \>2 groups were analyzed by one-way ANOVA with post hoc contrasts by the S-N-K method. A P-value of \<0.05 was considered to indicate a statistically significant difference.

Results
=======

### FAT1 exhibits a high frequency of mutations and shows downregulated expression in ESCC

In our previous study, we analyzed the genomic sequencing data from 4 ESCC cohorts, including 424 tumors and matched normal DNA samples, from patients recruited in the Taihang Mountain region of north-central China and Chaoshan District of Guangdong Province, the areas of high ESCC incidence in China. We found that FAT1 was mutated frequently in ESCC. The total mutation rate was \~13.4% (57/424), including nonsense in 21/57 (36.8%), missense in 22/57 (38.6%), insertion or deletion in 14/57 (24.6%) in these 4 cohorts ([@b6-or-39-05-2136],[@b8-or-39-05-2136],[@b20-or-39-05-2136]--[@b22-or-39-05-2136]). In addition, we analyzed several types of squamous cell carcinomas in a TCGA database using cBioPortal ([@b23-or-39-05-2136],[@b24-or-39-05-2136]), and found that FAT1 was mutated frequently in squamous cell carcinomas ([Fig. 1A](#f1-or-39-05-2136){ref-type="fig"}). In ESCC, the frequency of FAT1 mutations was 11.7% ([@b20-or-39-05-2136]), in head and neck squamous cell carcinoma (HNSCC), the frequency of FAT1 mutations was 21.7% ([@b23-or-39-05-2136]), in lung squamous cell carcinoma (LSCC), the frequency of FAT1 mutations was 14.6% ([@b25-or-39-05-2136]), and in oral squamous cell carcinoma (OSCC), the frequency of FAT1 mutations was 30% ([@b26-or-39-05-2136]). Then, we detected FAT1 protein expression via TMA that included 76 cases of primary esophageal tumor tissues and matched adjacent non-tumor tissues, since the other 49 cases of tissues were incomplete for further statistics. We observed that FAT1 expression was strongly lower in the tumor tissues than that noted in the stained non-tumor tissues ([Fig. 1B](#f1-or-39-05-2136){ref-type="fig"}). Data on the 125 patients from which the tumor and normal samples were derived for the TMA study are provided in [Table I](#tI-or-39-05-2136){ref-type="table"}.

### Knockdown of FAT1 in ESCC cells

First, we measured FAT1 mRNA levels in non-transformed esophageal epithelial SHEE cells and 8 ESCC cell lines by RT-PCR and in-cell western assay and found different expression levels in the various of ESCC cell lines ([Fig. 2A and B](#f2-or-39-05-2136){ref-type="fig"}). Of these cell lines, YSE2 and Colo680N cell lines with a relative high endogenous FAT1 level were used for the knockdown experiment. The transfection efficiency of YSE2 and Colo680N cells was \>90% ([Fig. 2C](#f2-or-39-05-2136){ref-type="fig"}). RT-PCR and qPCR were used to assess the mRNA expression of FAT1 in the FAT1-knockdown ESCC cells ([Fig. 2D](#f2-or-39-05-2136){ref-type="fig"}). In-cell western assay was used to assess the protein of FAT1 in FAT1-knockdown ESCC cells ([Fig. 2E](#f2-or-39-05-2136){ref-type="fig"}). The data showed that the efficiency of knockdown was \>70%.

### FAT1 knockdown promotes cell migration and invasion in ESCC

Transwell assays were performed to examine the effect of FAT1 on the migration and invasion of ESCC cells. The results showed that FAT1 depletion led to a significant increase in cell migration and invasion abilities in the YSE2 and Colo680N cell lines ([Fig. 3A and B](#f3-or-39-05-2136){ref-type="fig"}), which were also confirmed by the wound healing migration assay ([Fig. 3C](#f3-or-39-05-2136){ref-type="fig"}).

### Changes in the morphologic and biomechanical properties of the ESCC cells after FAT1 knockdown as determined by AFM

In the present study, AFM was used to visualize the morphology of YSE2 and Colo680N FAT1-knockdown cells in comparison to the corresponding control groups, respectively. The results demonstrated that the cells became relatively thinner following FAT1 knockdown. In addition, we detected the roughness of the cell membrane surface. The results showed that, although the cell surface roughness in the FAT1-knockdown cells had no statistical difference when compared with the NC group, there was a downward trend. The results indicate that the cell surface may be smoother after knockdown of FAT1 ([Fig. 4](#f4-or-39-05-2136){ref-type="fig"}).

Furthermore, compared to the NC groups, the adhesive force was significantly reduced (YSE2NC, 1200±300 pN vs. FAT1shRNA, 480±200 pN; Colo680NNC, 1400±400 pN vs. FAT1shRNA, 560±230 pN), while the elasticity force was markedly increased (YSE2NC, 3.9±0.7 MPa vs. FAT1shRNA, 19±6.3 MPa; Colo680NNC, 4.2±1.3 MPa vs. FAT1shRNA, 26±5.5 MPa) in the YSE2-FAT1shRNA and Colo680N-FAT1shRNA groups, and the difference was statistically significant ([Fig. 5](#f5-or-39-05-2136){ref-type="fig"}). Taken together, these results suggest that FAT1 may affect cell microscopic morphology and mechanical properties consequently impacting ESCC cell migration and invasion ability.

Discussion
==========

As one of the members of the cadherin family, FAT atypical cadherin 1 (FAT1) is regarded as a key molecule that regulates cellular growth, migration and orientation. The effect of FAT1 on tumor occurrence and development is still in discussion ([@b27-or-39-05-2136]). The dual role of FAT1 in human cancer development has been reported as it functions as both a tumor-suppressor gene as well as an oncogene ([@b9-or-39-05-2136]--[@b11-or-39-05-2136],[@b28-or-39-05-2136]). FAT1 was first deemed to posses a tumor suppressive function in *Drosophila melanogaster* by regulating the Salvador/Warts/Hippo signaling pathway ([@b29-or-39-05-2136],[@b30-or-39-05-2136]). In glioblastoma multiforme, colorectal cancer and head and neck cancer, FAT1 was identified as a tumor suppressor, for which somatic mutations lead to aberrant Wnt signaling pathway activation ([@b12-or-39-05-2136]). In breast carcinoma, suppression of FAT1 expression was found to promote breast cancer cell invasion ([@b31-or-39-05-2136]). However, in hepatocellular carcinoma, FAT1 acts as a tumor promoter and promotes the proliferation and migration as well as inhibits apoptosis ([@b11-or-39-05-2136]). The possible switch of FAT1 from an oncogene to an oncogenesis-preventive gene may be due to the specificity of the tissues and organs and the complexity of the signaling pathways. In our previous study, we identified a novel role of FAT1 in inhibiting tumor growth and EMT occurrence in ESCC by means of disruption of the MAPK/ERK pathway ([@b8-or-39-05-2136]). In the present study, we further identified the tumor-suppressor function of FAT1 in light of the changes in the morphologic and biomechanical properties of the cells using AFM.

A change in cell mechanical properties can affect the body\'s physiological function and cause disease ([@b32-or-39-05-2136]); in particular, cell mechanical properties play an important role in the study of human cancer ([@b33-or-39-05-2136],[@b34-or-39-05-2136]). In recent years, more and more research has shown that AFM can be used as a tool for the detection of the biological behaviors of tumor cells and for assessment of antitumor efficacy ([@b35-or-39-05-2136]). Cell adhesion and elasticity force may reflect the cell membrane and cytoskeleton mechanics state and are associated with cellular deformability ([@b36-or-39-05-2136]). Increased cell adhesion strength and decreased elasticity lead to deformation capacity reduction. Tumor cells need deformation to complete migration, invasion and a series of biological behaviors ([@b37-or-39-05-2136]). Propofol was found to decrease the migratory ability by influencing the cell cytoskeleton in cervical cancer cell lines ([@b38-or-39-05-2136]). Lian *et al* reported that artesunate attenuates cellular migration and invasion by affecting cellular mechanical properties in glioma ([@b39-or-39-05-2136]). In addition, studies have shown that the mechanical properties of cells and tissues as determined by AFM can be used as markers for the diagnosis of various pathological conditions such as cancer, arthritis, osteoporosis ([@b40-or-39-05-2136]), pulmonary fibrosis ([@b41-or-39-05-2136]), blood and cardiovascular pathologies ([@b40-or-39-05-2136]). Therefore, we speculate that AFM may serve as a means of clinical laboratory examination in the future. In the present study, we detected cell adhesive force and cell elasticity force by AFM and found that suppression of endogenous expression of FAT1 led to a decrease in cell adhesive force and an increase in cell elasticity force compared with the control groups.

Although FAT1 was recently implicated as a tumor suppressor or an oncogene in other cancers, its roles in ESCC are limited. In our previous research, we found that FAT1 was one of the significantly mutated genes in ESCC and FAT1 expression was decreased in ESCC tissues compared with that noted in matched normal adjacent tissues ([@b8-or-39-05-2136]). In the present study, we verified that FAT1 knockdown effectively accelerated cell migration and invasion. Moreover, the impact of FAT1 disruption on the cellular mechanical properties was also evaluated by AFM. The cytoskeleton consists of microtubules, microfilaments and microvilli, which determines the cell morphology and biomechanical characteristics under various physiological and pathological statuses ([@b42-or-39-05-2136]). Yao *et al* showed that MARVELD1, a potential tumor suppressor, increased the length of microvilli and suppressed EMT in non-small cell lung cancer ([@b43-or-39-05-2136]). In breast cancer MCF-7 cell lines, rhBMP-2 was found to promote EMT progression and AFM observation showed that the MCF-7 cells became narrower and flatter, with lamellipodia formation following rhBMP-2 treatment ([@b44-or-39-05-2136]). Our previous study showed that FAT1 prevented EMT and inhibited the migration and invasion of ESCC cells. Our present study showed that FAT1 may affect cytoskeleton proteins, and therefore alter the ability of cell migration and invasion. The specific mechanism will be explored in subsequent research.

In conclusion, the present study showed that FAT1 inhibited cell migration and invasion by affecting the cellular mechanical properties of ESCC cells. The present findings aid in our understanding of the potential mechanisms that drive the development of ESCC and may provide new insight concerning the association between FAT1 and ESCC.
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###### 

FAT1 mutations frequently occur in ESCC and other squamous cell carcinomas, and FAT1 exhibits downregulated expression in ESCC. (A) The frequency of mutations of FAT1 in four types of squamous cell carcinomas (ESCC, esophageal squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; LSCC, lung squamous cell carcinoma; OSCC, oral squamous cell carcinoma) in the TCGA database. (B) Overall and representative images of FAT1 expression in tumor tissues (T) and adjacent non-tumor tissues (N) from paraffin-embedded formalin-fixed ESCC tissue microarrays containing 76 tumors and corresponding non-tumor tissues by IHC. Left panel: magnification ×10 (scale bar, 4 µm); right upper panel: magnification ×200 (scale bar, 100 µm); right lower panel: statistical analysis of FAT1 protein level based on TMA data. FAT1, FAT atypical cadherin 1.

![](OR-39-05-2136-g00)

![](OR-39-05-2136-g01)

![Verification of the knockdown efficiency of FAT1 in YSE2 and Colo680N cells. (A) The mRNA expression pattern of FAT1 in non-transformed esophageal epithelial SHEE cells and 8 ESCC cell lines as detected by qPCR (upper panel) and RT-PCR (Lower panel). (B) Upper panel: FAT1 protein level in non-transformed esophageal epithelial SHEE cells and 8 ESCC cell lines as detected by in-cell western assay. Channel 700 represents cell number and channel 800 represents FAT1. The merge represents the protein expression of FAT1 in these cells. Lower panel: Quantification of the protein level of FAT1 in various ESCC cell lines. (C) Examination of the transfection efficiency of the FAT1shRNA plasmid into the YSE2 and Colo680N cells by fluorescence microscopy (scale bar, 100 µm). (D) Knockdown efficiency of FAT1 in YSE2 and Colo680N cells was verified by qPCR (upper panel) and RT-PCR (lower panel). (E) Knockdown efficiency of FAT1 in YSE2 (left panel) and Colo680N cells (right panel) was verified in-cell western assay. Channel 700 represents cell number and channel 800 represents FAT1. The merge represents the protein expression of FAT1 in these cells. All experiments were repeated three times independently. FAT1, FAT atypical cadherin 1.](OR-39-05-2136-g02){#f2-or-39-05-2136}

![Silencing of FAT1 accelerates cell migration and invasion in YSE2 and Colo680N cells. (A) Silencing of FAT1 promoted the migration and invasion of YSE2 and Colo680N cells. Representative images of the migration and invasion assays are shown (scale bar, 100 µm). (B) Histograms showing that FAT1 inhibition promoted the ability of cell migration and invasion. (C) Cell migration as monitored by wound healing assay was carried out in YSE2 and Colo680N cells. The wound area was calculated using ImageJ software. All experiments were repeated three times independently. \*P\<0.05, \*\*P\<0.01. FAT1, FAT atypical cadherin 1.](OR-39-05-2136-g03){#f3-or-39-05-2136}

![The morphological images of YSE2 and Colo680N cells following FAT1 knockdown and the matched negative control groups by atomic force microscopy (AFM). (A) The 2D cell morphology of YSE2 and Colo680N cells following FAT1 knockdown and the matched negative control (NC) groups by AFM. A1, NC group (YSE2 cells); A2, FAT1-knockdown group (YSE2 cells); A3, NC group (Colo680N cells); A4, FAT1-knockdown group (Colo680N cells). (B) 3D cell morphology. B1, NC group (YSE2 cells); B2, FAT1-knockdown group (YSE2 cells); B3, NC group (Colo680N cells); B4, FAT1-knockdown group (Colo680N cells). (C) The cell ultra-structure of YSE2 and Colo680N cells of the FAT1-knockdown and matched negative groups by AFM. C1, NC group (YSE2 cells); C2, FAT1-knockdown group (YSE2 cells); C3, NC group (Colo680N cells); C4, FAT1-knockdown group (Colo680N cells). (D) The statistical histogram of average roughness of the cytomembrane of ESCC cells with or without FAT1 knockdown. All experiments were repeated three times independently. \*P\<0.05, \*\*P\<0.01. FAT1, FAT atypical cadherin 1.](OR-39-05-2136-g04){#f4-or-39-05-2136}

![AFM force-distance curve analyses to detect the adhesive force and elasticity of YSE2 and Colo680N cells in the FAT1-knockdown and matched negative groups. (A) Adhesion force histograms showing the adhesive force and elasticity of YSE2 and Colo680N cells in the FAT1-knockdown and matched negative control (NC) groups by atomic force microscopy (AFM). A1, NC group (YSE2 cells); A2, FAT1-knockdown group (YSE2 cells); A3, NC group (Colo680N cells); A4, FAT1-knockdown group (Colo680N cells). (B) Adhesion force map of the same cell-surface area. B1, NC group (YSE2 cells); B2, FAT1-knockdown group (YSE2 cells); B3, NC group (Colo680N cells); B4, FAT1-knockdown group (Colo680N cells). (C) Elasticity histogram. C1, NC group (YSE2 cells); C2, FAT1-knockdown group (YSE2 cells); C3, NC group (Colo680N cells); C4, FAT1-knockdown group (Colo680N cells). (D) Elasticity map of the same cell-surface area. D1, NC group (YSE2 cells); D2, FAT1-knockdown group (YSE2 cells); D3, NC group (Colo680N cells); D4, FAT1-knockdown group (Colo680N cells). (E) Statistical histogram showing the adhesive force of ESCC cells with or without FAT1 knockdown. (F) Statistical histogram of the elasticity force of ESCC cells with or without FAT1 knockdown. All experiments were repeated three times independently. \*P\<0.05, \*\*P\<0.01. FAT1, FAT atypical cadherin 1. pN, picoNewton (10^−12^ N); MPa, mega Pascal (10^6^ Pa).](OR-39-05-2136-g05){#f5-or-39-05-2136}

###### 

Information concerning the 125 patients in the tissue microarray study.

  Characteristics    No. of cases (N=125)
  ------------------ ----------------------
  Age (years)        
    \<60             69
    ≥60              56
  Sex                
    Male             86
    Female           39
  Smoking            
    No               46
    Yes              79
  Drinking           
    No               81
    Yes              44
  Family history     
    No               97
    Yes              28
  Differentiation    
    High               4
    Middle           89
    Low              32
  T Classification   
    T1               10
    T2               27
    T3               88
    T4                 0
  N classification   
    N \<1            47
    N ≥1             78
  TNM stage          
    I                  6
    II               50
    III              68
    IV                 1

[^1]: Contributed equally
